https://www.selleckchem.com/products/brd0539.html
XELAVIRI compared sequential (Arm A) versus initial (Arm irinotecan in combination with fluoropyrimidine plus bevacizumab in patients with metastatic colorectal cancer, trial identification NCT01249638. In the full analysis set of the study, non-inferiority of time to failure of strategy (TFS) was not shown. The present analysis was performed to evaluate the effect of gender on treatment outcome and tolerability. The study end-points overall response rate (ORR), progression-free survival (PFS), TFS and overall survival (OS) were eval
Like
Comment
Share
